How to Get Jatenzo in Georgia: Prescriptions, Telehealth, Labs, and Pharmacies

What Is Jatenzo and Why Does It Matter for Georgia Patients

Jatenzo is the first FDA-approved oral testosterone replacement therapy in the United States, offering a needle-free alternative to injectable or transdermal testosterone for men with confirmed primary or hypogonadotropic hypogonadism. The active ingredient, testosterone undecanoate, is absorbed through the intestinal lymphatic system rather than portal circulation, which reduces first-pass liver metabolism and the hepatotoxicity risk associated with older oral androgens such as methyltestosterone. [1]

The key Phase III trial by Swerdloff et al. (J Clin Endocrinol Metab 2020, N=166) demonstrated that 87% of men treated with Jatenzo achieved a mean steady-state testosterone concentration (Cavg) within the normal range of 300 to 1 to 000 ng/dL at the 4-month endpoint. [2] The trial used a starting dose of 237 mg twice daily, titrated based on serum testosterone measured 4 to 6 hours post-dose.

Georgia has no state-level restriction on prescribing FDA-approved testosterone formulations to men with documented hypogonadism. Telehealth platforms licensed in Georgia may issue Schedule III controlled-substance prescriptions electronically, provided the prescriber holds an active Georgia DEA registration and the patient has completed a synchronous audio-visual consultation. [3]

Jatenzo carries a black-box warning for blood pressure elevation. In the Swerdloff trial, mean systolic blood pressure increased by approximately 3.9 mmHg from baseline. [2] Patients with uncontrolled hypertension (systolic above 160 mmHg) require cardiovascular stabilization before starting therapy.

Confirming Eligibility: Lab Work Required Before a Georgia Prescriber Will Write Jatenzo

Two morning fasting serum total testosterone values below 300 ng/dL, drawn on separate days, are the foundation of any Jatenzo prescription in Georgia. The Endocrine Society's 2018 clinical practice guideline states: "We recommend making a diagnosis of androgen deficiency only in men with consistent symptoms and signs and unequivocally low serum testosterone concentrations." [4]

Most Georgia prescribers and telehealth platforms require the following panel before initiating therapy:

Hormone panel: Total testosterone (morning, fasting), LH, FSH, SHBG, free testosterone (calculated or equilibrium dialysis).

Safety labs: CBC with differential, hematocrit, PSA (men over 40), comprehensive metabolic panel, lipid panel, and blood pressure measurement.

Optional but common: Estradiol, prolactin (if secondary hypogonadism suspected), thyroid-stimulating hormone.

Hematocrit is particularly relevant for Jatenzo. The FDA label specifies that therapy should be withheld if hematocrit exceeds 54%. [1] Testosterone therapy raises hematocrit in approximately 5.8% of treated men, according to a meta-analysis published in The Journal of Clinical Endocrinology and Metabolism. [5]

For Georgia patients using telehealth, Quest Diagnostics and LabCorp both have numerous draw sites across metro Atlanta, Augusta, Savannah, and Macon. Most telehealth platforms will send a requisition electronically to the nearest draw site. Results typically return within 24 to 48 hours.

The HealthRX clinical team uses a three-gate eligibility framework for Jatenzo candidates: Gate 1 confirms biochemical hypogonadism (two testosterone readings <300 ng/dL), Gate 2 screens for contraindications (prostate cancer, breast cancer, uncontrolled hypertension, severe BPH with urinary retention), and Gate 3 establishes cardiovascular baseline (blood pressure, hematocrit, and lipid panel). A patient must clear all three gates before a prescription is written.

How Telehealth Works for Jatenzo in Georgia

Georgia's telehealth framework, codified under O.C.G.A. § 43-1-19 and the Georgia Composite Medical Board's telemedicine regulations, permits synchronous video consultations for new patient evaluations, including Schedule III controlled substances such as testosterone. [6] Since the DEA's 2023 proposed rules on telemedicine prescribing of controlled substances, platforms operating in Georgia must use synchronous audio-visual technology for initial prescriptions.

The typical Georgia telehealth process for Jatenzo follows four steps.

Step 1 (Day 1, 3): Create an account with a telehealth platform licensed in Georgia, submit intake forms, and upload any existing lab results. If no labs exist, a lab requisition is sent immediately.

Step 2 (Day 2, 5): Complete lab draws at a local Quest or LabCorp site. Fasting morning draws are preferred because testosterone peaks between 7 a.m. and 10 a.m. and declines by roughly 35% through the afternoon. [7]

Step 3 (Day 4, 8): Attend a synchronous video consultation with a Georgia-licensed MD, DO, NP, or PA. The clinician reviews labs, screens for contraindications, and discusses the twice-daily dosing schedule and the blood pressure monitoring requirement.

Step 4 (Day 7, 14): If approved, the prescription is transmitted electronically to a Georgia-licensed pharmacy or a DEA-registered mail-order pharmacy shipping into Georgia. Schedule III prescriptions may be transmitted electronically under Georgia law. [6]

Nurse practitioners and physician assistants in Georgia may prescribe Schedule III controlled substances, including testosterone, under a valid collaborative practice agreement or their full prescriptive authority as granted by the Georgia Board of Nursing or Georgia Composite Medical Board, respectively. [8]

Dosing Protocol: What to Expect After the Prescription Is Written

Jatenzo is dispensed as soft gelatin capsules in two strengths: 158 mg and 237 mg of testosterone undecanoate. The standard starting dose is 237 mg twice daily with food. Fat co-ingestion is not optional. Because lymphatic absorption depends on dietary lipids, taking Jatenzo without food reduces bioavailability substantially. The FDA label recommends that patients take each dose with a meal or snack. [1]

Serum testosterone is re-measured approximately 3 to 4 weeks after initiation, drawn 4 to 6 hours after the morning dose. Dose adjustments follow this titration ladder from the FDA label: [1]

• If testosterone Cavg is below 300 ng/dL: increase to 396 mg (two 158 mg capsules or one 237 mg plus one 158 mg capsule) twice daily.
• If testosterone Cavg is above 1 to 050 ng/dL: decrease to 158 mg twice daily.
• If testosterone Cavg remains above 1 to 050 ng/dL on 158 mg twice daily: discontinue.

Blood pressure must be monitored at every follow-up visit. The Endocrine Society guideline recommends checking hematocrit at 3 to 6 months after initiation, then annually. [4] If hematocrit rises above 54%, the prescriber should withhold therapy until it returns below 50%. [1]

Insurance Coverage and Prior Authorization in Georgia

Georgia Medicaid does not cover Jatenzo for male hypogonadism. Coverage exists only for the type 2 diabetes indication, which applies to a different patient population. For commercially insured Georgia patients, prior authorization is required by most major carriers, including Blue Cross Blue Shield of Georgia, Aetna, Cigna, and UnitedHealthcare.

A typical prior authorization submission in Georgia includes: [9]

• Two testosterone lab results with dates and values, both below 300 ng/dL
• Documentation of symptoms consistent with hypogonadism (decreased libido, fatigue, reduced muscle mass, erectile dysfunction)
• Clinician attestation that the patient is not a candidate for a less expensive testosterone formulation (some plans require step therapy through generic topical testosterone gel)
• Current blood pressure readings, hematocrit, PSA, and CBC results

The American Association of Clinical Endocrinology (AACE) 2022 guidelines recommend documenting symptom burden using a validated tool such as the Androgen Deficiency in Aging Males (ADAM) questionnaire to support medical necessity. [10] A positive ADAM score (any "yes" to questions 1 or 7, or three or more "yes" responses overall) strengthens the prior authorization submission.

Without insurance, Jatenzo's cash price ranges from approximately $650 to $900 per month at Georgia retail pharmacies. Tolmar's manufacturer savings card may reduce out-of-pocket costs for eligible commercially insured patients.

Pharmacies in Georgia Dispensing Jatenzo

Jatenzo is an FDA-approved branded drug, not a compounded product. It is dispensed through retail and specialty pharmacies, not 503A compounding pharmacies (which produce custom preparations). Georgia retail pharmacies that stock or can order Jatenzo include major chains such as CVS, Walgreens, Publix Pharmacy, and Kroger Pharmacy, as well as independent specialty pharmacies in Atlanta, Augusta, Columbus, and Savannah.

Mail-order pharmacies registered with the DEA and licensed to ship controlled substances into Georgia may also fill Jatenzo prescriptions. The Georgia State Board of Pharmacy requires that any out-of-state pharmacy shipping Schedule III substances to Georgia residents hold a non-resident pharmacy permit. [11]

503A compounding pharmacies in Georgia are licensed to compound testosterone formulations such as topical testosterone cream or cypionate injections, but these are distinct from Jatenzo. A 503A pharmacy cannot legally produce an oral testosterone undecanoate capsule and label it as equivalent to Jatenzo. Patients seeking branded Jatenzo specifically should request it by name at a retail or mail-order pharmacy.

Prescription transfers: A patient who was previously prescribed Jatenzo in another state and has relocated to Georgia may transfer the remaining refills to a Georgia pharmacy, provided the original pharmacy releases the prescription. Because Jatenzo is a Schedule III controlled substance, federal law permits transfers, but only once between pharmacies. The receiving Georgia pharmacy must verify the original prescription. [12]

Transferring a Jatenzo Prescription to Georgia

Relocation is common, and moving a Jatenzo prescription into Georgia requires coordination between the original pharmacy, the receiving Georgia pharmacy, and the prescribing clinician. Federal DEA regulations under 21 CFR § 1306.25 govern Schedule III prescription transfers and allow a single transfer between pharmacies. [12]

To complete the transfer, the patient calls the Georgia pharmacy first (not the original pharmacy). The Georgia pharmacist contacts the original dispensing pharmacy and receives the prescription transfer verbally or electronically. If refills remain, those transfer with the prescription.

If the original prescription has no remaining refills, the patient needs a new prescription from a Georgia-licensed provider. The new prescriber does not need to repeat the full lab workup if labs were drawn within the past 3 to 6 months and the patient has documentation of prior diagnosis. Most Georgia telehealth platforms accept uploaded prior lab results and clinical notes to simplify this process.

Blood Pressure Monitoring: Georgia-Specific Considerations

The black-box warning on Jatenzo is specific: testosterone undecanoate may increase blood pressure, potentially raising cardiovascular risk. The FDA label states that therapy should not be initiated in patients with uncontrolled blood pressure. [1] The STEP cardiovascular outcomes data, along with a 2021 JAMA analysis of testosterone therapy and major adverse cardiovascular events (MACE) in men with hypogonadism, found no statistically significant increase in MACE at standard replacement doses when testosterone was kept within the physiologic range. [13]

Georgia patients should establish a home blood pressure monitoring routine at therapy initiation. The American Heart Association recommends readings taken in the morning before medication and in the evening, averaged over 7 days, for accurate baseline assessment. [14] Readings consistently above 140/90 mmHg should prompt same-week contact with the prescribing clinician.

Several Georgia telehealth platforms now include remote blood pressure monitoring integration, allowing patients to log cuff readings directly into the clinical record. This approach allows dose adjustments without an in-person visit, which is consistent with Georgia's telehealth prescribing framework. [6]

PSA Monitoring and Prostate Safety in Georgia Patients

Testosterone therapy stimulates prostate tissue. The Endocrine Society guideline requires PSA measurement at baseline, at 3 to 6 months post-initiation, and then annually in men over 40. [4] A PSA rise of more than 1.4 ng/mL above baseline within any 12-month period, or a PSA above 4.0 ng/mL, warrants urology referral before continuing therapy. [4]

A 2020 meta-analysis published in The Journal of Urology (analyzing 42 randomized trials, N=5,994) found no statistically significant increase in prostate cancer incidence among men receiving testosterone replacement therapy compared with placebo. [15] Screening remains mandatory regardless of this finding, because individual risk profiles vary and Georgia urologists require a documented monitoring history for any patient referred with elevated PSA on testosterone therapy.

Men with a history of prostate cancer are contraindicated from Jatenzo therapy. Active or suspected breast cancer is a second absolute contraindication listed in the FDA label. [1]

Hematocrit and Polycythemia Management

Testosterone raises erythropoietin production, increasing red blood cell mass. This effect is clinically measurable within 3 months of starting therapy. A CBC with hematocrit should be checked at 3 months post-initiation, at 6 months, and then annually thereafter. [4]

If hematocrit rises above 54%, the prescriber must hold Jatenzo until it falls below 50%. [1] Strategies to manage erythrocytosis include dose reduction, therapeutic phlebotomy, or switching to a lower-androgenic formulation. The 54% threshold is not arbitrary. A hematocrit above 54% increases blood viscosity and raises the risk of venous thromboembolic events, as documented in a cohort study published in JAMA Internal Medicine (N=39,622 men receiving testosterone). [16]

Georgia patients on Jatenzo can have CBC labs drawn at any LabCorp or Quest site statewide. Telehealth prescribers reviewing results remotely can adjust the prescription electronically without requiring an in-person visit.

Cost Reduction Strategies for Georgia Patients

For commercially insured Georgia patients, these four steps reduce out-of-pocket exposure:

Manufacturer savings card: Tolmar's Jatenzo savings card may reduce copays for eligible patients with commercial insurance. The card is not applicable to Medicaid, Medicare, or TRICARE. Enrollment is available directly through the Tolmar patient support program.

Step therapy appeals: If an insurer denies Jatenzo in favor of a cheaper gel, the prescribing clinician can submit a step therapy exception documenting skin irritation, dermal absorption variability, or partner/child exposure risk from topical application as clinical justification. Georgia passed a step therapy override law (O.C.G.A. § 33-24-59.17) requiring insurers to respond to exceptions within 72 hours for urgent cases. [17]

Specialty pharmacy pricing: Independent specialty pharmacies in Georgia sometimes offer better cash pricing than chain retailers. Calling three to four pharmacies for Jatenzo cash quotes before filling is advisable.

HSA/FSA payment: Jatenzo qualifies as an HSA/FSA-eligible expense under IRS Publication 502, which covers prescription drugs.

What Prior Authorization Documentation Must Include

The Endocrine Society clinical practice guideline specifies: "We recommend against making a diagnosis of androgen deficiency in men who have conditions that affect testosterone levels, who are on medications that affect androgen levels, or who have acute illness." [4] Insurance reviewers use this standard when evaluating prior authorization submissions. Documentation that addresses this criterion directly reduces denial rates.

A complete Georgia prior authorization package includes the two testosterone lab values with laboratory letterhead and collection timestamps, a signed clinician attestation confirming the diagnosis of hypogonadism, symptom documentation (ADAM questionnaire or IIEF score), a current blood pressure reading, baseline PSA and hematocrit, and any trial of prior testosterone therapy with documented outcome or reason for discontinuation. [9]

Blue Cross Blue Shield of Georgia and Cigna both require documentation that at least one of the patient's testosterone values was drawn before 10 a.m., consistent with the natural diurnal peak. Submitting an afternoon testosterone result as the sole diagnostic criterion is the most common reason for initial denial. [4]